NDC 0002-7501 Gemzar

Gemcitabine Hydrochloride

NDC Product Code 0002-7501

NDC Product Information

Gemzar with NDC 0002-7501 is a a human prescription drug product labeled by Eli Lilly And Company. The generic name of Gemzar is gemcitabine hydrochloride. The product's dosage form is injection, powder, lyophilized, for solution and is administered via intravenous form.

Labeler Name: Eli Lilly And Company

Dosage Form: Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.

Product Type: Human Prescription Drug Additional informationCallout TooltipWhat kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.


Gemzar Active Ingredient(s)

Additional informationCallout TooltipWhat is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • GEMCITABINE HYDROCHLORIDE 200 mg/5mL

Inactive Ingredient(s)

Additional informationCallout TooltipAbout the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • MANNITOL (UNII: 3OWL53L36A)
  • SODIUM ACETATE (UNII: 4550K0SC9B)
  • SODIUM HYDROXIDE (UNII: 55X04QC32I)
  • HYDROCHLORIC ACID (UNII: QTT17582CB)

Administration Route(s)

Additional informationCallout TooltipWhat are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intravenous - Administration within or into a vein or veins.

Pharmacological Class(es)

Additional informationCallout TooltipWhat is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Nucleic Acid Synthesis Inhibitors - [MoA] (Mechanism of Action)
  • Nucleoside Metabolic Inhibitor - [EPC] (Established Pharmacologic Class)

Product Labeler Information

Additional informationCallout TooltipWhat is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

* Please review the disclaimer below.

Information for Patients

Gemcitabine Injection

Gemcitabine Injection is pronounced as (jem sit' a been)

Why is gemcitabine injection medication prescribed?
Gemcitabine is used in combination with other chemotherapy drugs to treat cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are forme...
[Read More]

* Please review the disclaimer below.

Gemzar Product Label Images

Gemzar Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

1.1 Ovarian Cancer

Gemzar in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.

1.2 Breast Cancer

Gemzar in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.

1.3 Non-Small Cell Lung Cancer

Gemzar is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer.

1.4 Pancreatic Cancer

Gemzar is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemzar is indicated for patients previously treated with 5-FU.

Other

Recommended Dose and ScheduleThe recommended dose of Gemzar is 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, in combination with carboplatin AUC 4 intravenously after Gemzar administration on Day 1 of each 21-day cycle. Refer to carboplatin prescribing information for additional information.

Dose ModificationsRecommended Gemzar dose modifications for myelosuppression are described in Table 1 and Table 2
[see Warnings and Precautions (5.2)]. Refer to Dosage and Administration (2.5) for recommendations for non-hematologic adverse reactions.
Table 1: Dosage Reduction Guidelines for Gemzar for Myelosuppression on Day of Treatment in Ovarian Cancer
Treatment Day
Absolute granulocyte count(x 106/L)
Platelet count(x 106/L)
% of full dose
Day 1
≥1500<1500
andor
≥100,000<100,000
100%Delay Treatment Cycle
Day 8
≥15001000-1499<1000
andoror
≥100,00075,000-99,999<75,000
100%50%Hold
Table 2: Gemzar Dose Modification for Myelosuppression in Previous Cycle In Ovarian Cancer
Occurrence
Myelosuppression During Treatment Cycle
Dose Modification
Initial Occurrence
Absolute granulocyte count less than 500 x 106/L for more than 5 daysAbsolute granulocyte count less than 100 x 106/L for more than 3 daysFebrile neutropeniaPlatelets less than 25,000x106/LCycle delay of more than one week due to toxicity
Permanently reduce Gemzar to 800 mg/m2 on Days 1 and 8
Subsequent Occurrence
If any of the above toxicities occur after the initial dose reduction
Permanently reduce Gemzar dose to 800 mg/m2 on Day 1 only

Recommended Dose and ScheduleThe recommended dose of Gemzar is 1250 mg/m2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle that includes paclitaxel. Paclitaxel should be administered at 175 mg/m2 on Day 1 as a 3 hour intravenous infusion before Gemzar administration.

Dose ModificationsRecommended dose modifications for Gemzar for myelosuppression are described in Table 3
[see Warnings and Precautions (5.2)]. Refer to Dosage and Administration (2.5) for recommendations for non-hematologic adverse reactions.
Table 3: Recommended Dose Reductions for Gemzar for Myelosuppression on Day of Treatment in Breast Cancer
Treatment Day
Absolute granulocyte count(x 106/L)
Platelet count(x 106/L)
% of full dose
Day 1
≥1500
and
≥100,000
100%
less than 1500
or
less than 100,000
Hold
Day 8
≥1200
and
>75,000
100%
1000-1199
or
50,000-75,000
75%
700-999
and
≥50,000
50%
<700
or
<50,000
Hold

Recommended Dose and Schedule

Every 4-week schedule
The recommended dose of Gemzar is 1000 mg/m2 intravenously over 30 minutes on Days 1, 8, and 15 in combination with cisplatin therapy. Administer cisplatin intravenously at 100 mg/m2 on Day 1 after the infusion of Gemzar.

Every 3-week schedule
The recommended dose of Gemzar is 1250 mg/m2 intravenously over 30 minutes on Days 1 and 8 in combination with cisplatin therapy. Administer cisplatin intravenously at 100 mg/m2 on Day 1 after the infusion of Gemzar.

Dose ModificationsRecommended dose modifications for Gemzar myelosuppression are described in Table 4
[see Warnings and Precautions (5.2)]. Refer to Dosage and Administration (2.5) for Gemzar recommendations for non-hematologic adverse reactions.

  • Recommended Dose and ScheduleThe recommended dose of Gemzar is 1000 mg/m2 over 30 minutes intravenously. The recommended treatment schedule is as follows:
  • Weeks 1-8: weekly dosing for the first 7 weeks followed by one week rest.
  • After week 8: weekly dosing on Days 1, 8, and 15 of 28-day cycles.

Dose ModificationsRecommended dose modifications for Gemzar for myelosuppression are described in Table 4
[see Warnings and Precautions (5.2)]. Refer to Dosage and Administration (2.5) for recommendations for non-hematologic adverse reactions.
Patients receiving Gemzar should be monitored prior to each dose with a complete blood count (CBC), including differential and platelet count. If marrow suppression is detected, therapy should be modified or suspended according to the guidelines in Table 4.
Table 4: Recommended Dose Reductions for Gemzar for Myelosuppression in Pancreatic Cancer and Non-Small Cell Lung Cancer
Absolute granulocyte count(x 106/L)
Platelet count(x 106/L)
% of full dose
≥1000
And
≥100,000
100%
500-999
Or
50,000-99,999
75%
<500
Or
<50,000
Hold

Concurrent (given together or ≤7 days apart) — Life-threatening mucositis, especially esophagitis and pneumonitis occurred in a trial in which Gemzar was administered at a dose of 1000 mg/m2 to patients with non-small cell lung cancer for up to 6 consecutive weeks concurrently with thoracic radiation.

Non-concurrent (given >7 days apart) — Excessive toxicity has not been observed when Gemzar is administered more than 7 days before or after radiation. Radiation recall has been reported in patients who receive Gemzar after prior radiation.

  • Single-Agent Use:The data described below reflect exposure to Gemzar as a single agent administered at doses between 800 mg/m2 to 1250 mg/m2 over 30 minutes intravenously, once weekly, in 979 patients with a variety of malignancies. The most common (≥20%) adverse reactions of single-agent Gemzar are nausea/vomiting, anemia, increased ALT, increased AST, neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and edema. The most common (≥5%) Grade 3 or 4 adverse reactions were neutropenia, nausea/vomiting; increased ALT, increase alkaline phosphatase, anemia, increased AST, and thrombocytopenia. Approximately 10% of the 979 patients discontinued Gemzar due to adverse reactions. Adverse reactions resulting in discontinuation of Gemzar in 2% of 979 patients were cardiovascular adverse events (myocardial infarction, cerebrovascular accident, arrhythmia, and hypertension) and adverse reactions resulting in discontinuation of Gemzar in less than 1% of the 979 patients were anemia, thrombocytopenia, hepatic dysfunction, renal dysfunction, nausea/vomiting, fever, rash, dyspnea, hemorrhage, infection, stomatitis, somnolence, flu-like syndrome, and edema.
  • Table 5 presents the incidence of adverse reactions reported in 979 patients with various malignancies receiving single-agent Gemzar across 5 clinical trials. Table 5 includes all clinical adverse reactions, reported in at least 10% of patients. A listing of clinically significant adverse reactions is provided following the table.
  • Table 5: Selected Per-Patient Incidence of Adverse Events in Patients Receiving Single-Agent Gemzaraa Grade based on criteria from the World Health Organization (WHO).
  • B N=699-974; all patients with laboratory or non-laboratory data.
  • C Regardless of causality.
  • D For approximately 60% of patients, non-laboratory adverse events were graded only if assessed to be possibly drug-related.
  • All PatientsbAll Grades
  • Grade 3
  • Grade 4
  • Laboratoryc     Hematologic
  • Anemia
  • 68
  • 7
  • 1
  • Neutropenia
  • 63
  • 19
  • 6
  • Thrombocytopenia
  • 24
  • 4
  • 1
  • Hepatic
  • Increased ALT
  • 68
  • 8
  • 2
  • Increased AST
  • 67
  • 6
  • 2
  • Increased Alkaline Phosphatase
  • 55
  • 7
  • 2
  • Hyperbilirubinemia
  • 13
  • 2
  • <1
  • Renal
  • Proteinuria
  • 45
  • <1
  • 0
  • Hematuria
  • 35
  • <1
  • 0
  • Increased BUN
  • 16
  • 0
  • 0
  • Increased Creatinine
  • 8
  • <1
  • 0
  • Non-laboratoryd     Nausea and Vomiting
  • 69
  • 13
  • 1
  • Fever
  • 41
  • 2
  • 0
  • Rash
  • 30
  • <1
  • 0
  • Dyspnea
  • 23
  • 3
  • <1
  • Diarrhea
  • 19
  • 1
  • 0
  • Hemorrhage
  • 17
  • <1
  • <1
  • Infection
  • 16
  • 1
  • <1
  • Alopecia
  • 15
  • <1
  • 0
  • Stomatitis
  • 11
  • <1
  • 0
  • Somnolence
  • 11
  • <1
  • <1
  • Paresthesias
  • 10
  • <1
  • 0
  • Transfusion requirements — Red blood cell transfusions (19%); platelet transfusions (<1%)
  • Fever — Fever occurred in the absence of clinical infection and frequently in combination with other flu-like symptoms.
  • Pulmonary — Dyspnea unrelated to underlying disease and sometimes accompanied by bronchospasm.
  • Edema — Edema (13%), peripheral edema (20%), and generalized edema (<1%); <1% of patients. discontinued Gemzar due to edema.
  • Flu-like Symptoms — Characterized by fever, asthenia, anorexia, headache, cough, chills, myalgia, asthenia insomnia, rhinitis, sweating, and/or malaise (19%); <1% of patients discontinued Gemzar due to flu-like symptoms
  • Infection — Sepsis (<1%)
  • Extravasation — Injection-site reactions (4%)
  • Allergic — Bronchospasm (<2%); anaphylactoid reactions [see Contraindications (4)].

Non-Small Cell Lung Cancer:Table 6 presents the incidence of selected adverse reactions, occurring in ≥10% of Gemzar-treated patients and at a higher incidence in the Gemzar plus cisplatin arm, reported in a randomized trial of Gemzar plus cisplatin (n=262) administered in 28-day cycles as compared to cisplatin alone (n=260) in patients receiving first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) [see Clinical Studies (14.3)].
Patients randomized to Gemzar plus cisplatin received a median of 4 cycles of treatment and those randomized to cisplatin received a median of 2 cycles of treatment. In this trial, the requirement for dose adjustments (>90% versus 16%), discontinuation of treatment for adverse reactions (15% versus 8%), and the proportion of patients hospitalized (36% versus 23%) were all higher for patients receiving Gemzar plus cisplatin arm compared to those receiving cisplatin alone. The incidence of febrile neutropenia (9/262 versus 2/260), sepsis (4% versus 1%), Grade 3 cardiac dysrhythmias (3% versus <1%) were all higher in the Gemzar plus cisplatin arm compared to the cisplatin alone arm. The two-drug combination was more myelosuppressive with 4 (1.5%) possibly treatment-related deaths, including 3 resulting from myelosuppression with infection and one case of renal failure associated with pancytopenia and infection. No deaths due to treatment were reported on the cisplatin arm.
Table 6: Per-Patient Incidence of Selected Adverse Reactions from Randomized Trial of Gemzar plus Cisplatin versus Single-Agent Cisplatin in Patients with NSCLC Occurring at Higher Incidence in Gemzar-Treated Patients [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)]aa National Cancer Institute Common Toxicity Criteria (CTC) for severity grading.
b N=217-253; all Gemzar plus cisplatin patients with laboratory or non-laboratory data Gemzar at 1000 mg/m2 on Days 1, 8, and 15 and cisplatin at 100 mg/m2 on Day 1 every 28 days.
c N=213-248; all cisplatin patients with laboratory or non-laboratory data. Cisplatin at 100 mg/m2 on Day 1 every 28 days.
d Regardless of causality.
e Percent of patients receiving transfusions. Percent transfusions are not CTC-graded events.
f Non-laboratory events were graded only if assessed to be possibly drug-related.
Gemzar plus CisplatinbCisplatincAll Grades
Grade 3
Grade 4
All Grades
Grade 3
Grade 4
Laboratoryd       Hematologic
         Anemia
89
22
3
67
6
1
         RBC Transfusione39
13
         Neutropenia
79
22
35
20
3
1
         Thrombocytopenia
85
25
25
13
3
1
         Platelet Transfusionse21
<1
         Lymphopenia
75
25
18
51
12
5
     Hepatic
         Increased Transaminases
22
2
1
10
1
0
         Increased Alkaline Phosphatase
19
1
0
13
0
0
     Renal
         Proteinuria
23
0
0
18
0
0
         Hematuria
15
0
0
13
0
0
         Elevated creatinine
38
4
<1
31
2
<1
     Other Laboratory
         Hyperglycemia
30
4
0
23
3
0
         Hypomagnesemia
30
4
3
17
2
0
         Hypocalcemia
18
2
0
7
0
<1
Non-laboratoryf     Nausea
93
25
2
87
20
<1
     Vomiting
78
11
12
71
10
9
     Alopecia
53
1
0
33
0
0
     Neuro Motor
35
12
0
15
3
0
     Diarrhea
24
2
2
13
0
0
     Neuro Sensory
23
1
0
18
1
0
     Infection
18
3
2
12
1
0
     Fever
16
0
0
5
0
0
     Neuro Cortical
16
3
1
9
1
0
     Neuro Mood
16
1
0
10
1
0
     Local
15
0
0
6
0
0
     Neuro Headache
14
0
0
7
0
0
     Stomatitis
14
1
0
5
0
0
     Hemorrhage
14
1
0
4
0
0
     Hypotension
12
1
0
7
1
0
     Rash
11
0
0
3
0
0
Table 7 presents the incidence of selected adverse reactions, occurring in ≥10% of Gemzar-treated patients and at a higher incidence in the Gemzar plus cisplatin arm, reported in a randomized trial of Gemzar plus cisplatin (n=69) administered in 21-day cycles as compared to etoposide plus cisplatin alone (n=66) in patients receiving first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) [see Clinical Studies (14.3)]. A listing of clinically significant adverse reactions is provided following the table.
Patients in the Gemzar cisplatin (GC) arm received a median of 5 cycles and those in the etoposide/cisplatin (EC) arm received a median of 4 cycles. The majority of patients receiving more than one cycle of treatment required dose adjustments; 81% in the (GC) arm and 68% in the (EC) arm. The incidence of hospitalizations for treatment-related adverse events was 22% (GC) and 27% in the (EC) arm. The proportion of discontinuation of treatment for treatment-related adverse reactions was higher for patients in the (GC) arm (14% versus 8%). The proportion of patients hospitalized for febrile neutropenia was lower in the (GC) arm (7% versus 12%). There was one death attributed to treatment, a patient with febrile neutropenia and renal failure, which occurred in the Gemzar/cisplatin arm.
Table 7: Per-Patient Incidence of Selected Adverse Reactions in Randomized Trial of Gemzar plus Cisplatin versus Etoposide plus Cisplatin in Patients with NSCLCaa Grade based on criteria from the World Health Organization (WHO).
b N=67-69; all Gemzar plus cisplatin patients with laboratory or non-laboratory data. Gemzar at 1250 mg/m2 on Days 1 and 8 and cisplatin at 100 mg/m2 on Day 1 every 21 days.
c N=57-63; all cisplatin plus etoposide patients with laboratory or non-laboratory data. Cisplatin at 100 mg/m2 on Day 1 and intravenous etoposide at 100 mg/m2 on Days 1, 2, and 3 every 21 days.
d Regardless of causality.
e WHO grading scale not applicable to proportion of patients with transfusions.
f Non-laboratory events were graded only if assessed to be possibly drug-related. Pain data were not collected.
g Flu-like syndrome and edema were not graded.
Gemzar plus CisplatinbEtoposide plus CisplatincAll Grades
Grade 3
Grade 4
All Grades
Grade 3
Grade 4
Laboratoryd     Hematologic
         Anemia
88
22
0
77
13
2
         RBC Transfusionse29
-
-
21
-
-
         Neutropenia
88
36
28
87
20
56
         Thrombocytopenia
81
39
16
45
8
5
         Platelet Transfusionse3
-
-
8
-
-
     Hepatic
         Increased ALT
6
0
0
12
0
0
         Increased AST
3
0
0
11
0
0
         Increased Alkaline Phosphatase
16
0
0
11
0
0
         Bilirubin
0
0
0
0
0
0
     Renal
         Proteinuria
12
0
0
5
0
0
         Hematuria
22
0
0
10
0
0
         BUN
6
0
0
4
0
0
         Creatinine
2
0
0
2
0
0
Non-laboratoryf         Nausea and Vomiting
96
35
4
86
19
7
         Fever
6
0
0
3
0
0
         Rash
10
0
0
3
0
0
         Dyspnea
1
0
1
3
0
0
         Diarrhea
14
1
1
13
0
2
         Hemorrhage
9
0
3
3
0
3
         Infection
28
3
1
21
8
0
         Alopecia
77
13
0
92
51
0
         Stomatitis
20
4
0
18
2
0
         Somnolence
3
0
0
3
2
0
         Paresthesias
38
0
0
16
2
0
         Flu-like syndromeg3
-
-
0
-
-
         Edemag12
-
-
2
-
-

Breast CancerTable 8 presents the incidence of selected adverse reactions, occurring in ≥10% of Gemzar-treated patients and at a higher incidence in the Gemzar plus paclitaxel arm, reported in a randomized trial of Gemzar plus paclitaxel (n=262) compared to paclitaxel alone (n=259) for the first-line treatment of metastatic breast cancer (MBC) in women who received anthracycline-containing chemotherapy in the adjuvant/neo-adjuvant setting or for whom anthracyclines were contraindicated [see Clinical Studies (14.2)].
The requirement for dose reduction of paclitaxel were higher for patients in the Gemzar/paclitaxel arm (5% versus 2%). The number of paclitaxel doses omitted (<1%), the proportion of patients discontinuing treatment for treatment-related adverse reactions (7% versus 5%), and the number of treatment-related deaths (1 patient in each arm) were similar between the two arms.
Table 8: Per-Patient Incidence of Selected Adverse Reactions from Comparative Trial of Gemzar plus Paclitaxel versus Single-Agent Paclitaxel in Breast Cancera Occurring at Higher Incidence in Gemzar-Treated Patients [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)]
a Severity grade based on National Cancer Institute Common Toxicity Criteria (CTC) Version 2.0.
b Regardless of causality.
c Non-laboratory events were graded only if assessed to be possibly drug-related.
Gemzar plus Paclitaxel(N=262)Paclitaxel(N=259)All Grades
Grade 3
Grade 4
All Grades
Grade 3
Grade 4
Laboratoryb     Hematologic
         Anemia
69
6
1
51
3
<1
         Neutropenia
69
31
17
31
4
7
         Thrombocytopenia
26
5
<1
7
<1
<1
     Hepatobiliary
         Increased ALT
18
5
<1
6
<1
0
         Increased AST
16
2
0
5
<1
0
Non-laboratoryc     Alopecia
90
14
4
92
19
3
     Neuropathy-sensory
64
5
<1
58
3
0
     Nausea
50
1
0
31
2
0
     Fatigue
40
6
<1
28
1
<1
     Vomiting
29
2
0
15
2
0
     Diarrhea
20
3
0
13
2
0
     Anorexia
17
0
0
12
<1
0
     Neuropathy-motor
15
2
<1
10
<1
0
     Stomatitis/pharyngitis
13
1
<1
8
<1
0
     Fever
13
<1
0
3
0
0
     Rash/desquamation
11
<1
<1
5
0
0
    Febrile neutropenia
6
5
<1
2
1
0
Clinically relevant Grade 3 or 4 dyspnea occurred with a higher incidence in the Gemzar plus paclitaxel arm compared with the paclitaxel arm (1.9% versus 0).

Ovarian CancerTable 9 presents the incidence of selected adverse reactions, occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the Gemzar plus carboplatin arm, reported in a randomized trial of Gemzar plus carboplatin (n=175) compared to carboplatin alone (n=174) for the second-line treatment of ovarian cancer in women with disease that had relapsed more than 6 months following first-line platinum-based chemotherapy [see Clinical Studies (14.1)]. Additional clinically significant adverse reactions, occurring in less than 10% of patients, are provided following Table 9.
The proportion of patients with dose adjustments for carboplatin (1.8% versus 3.8%), doses of carboplatin omitted (0.2% versus 0), and discontinuing treatment for treatment-related adverse reactions (10.9% versus 9.8%), were similar between arms. Dose adjustment for Gemzar occurred in 10.4% of patients and Gemzar dose was omitted in 13.7% of patients in the Gemzar /carboplatin arm.
Table 9: Per-Patient Incidence of Adverse Reactions in Randomized Trial of Gemzar plus Carboplatin versus Carboplatin in Ovarian Cancera Occurring at Higher Incidence in Gemzar-Treated Patients [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)]
a Grade based on Common Toxicity Criteria (CTC) Version 2.0.
b Regardless of causality.
c Percent of patients receiving transfusions. Transfusions are not CTC-graded events. Blood transfusions included both packed red blood cells and whole blood.
Gemzar plus Carboplatin(N=175)Carboplatin(N=174)All Grades
Grade 3
Grade 4
All Grades
Grade 3
Grade 4
Laboratoryb     Hematologic
         Neutropenia
90
42
29
58
11
1
         Anemia
86
22
6
75
9
2
         Thrombocytopenia
78
30
5
57
10
1
         RBC Transfusionsc38
15
         Platelet Transfusionsc9
3
Non-laboratoryb     Nausea
69
6
0
61
3
0
     Alopecia
49
0
0
17
0
0
     Vomiting
46
6
0
36
2
<1
     Constipation
42
6
1
37
3
0
     Fatigue
40
3
<1
32
5
0
     Diarrhea
25
3
0
14
<1
0
     Stomatitis/pharyngitis
22
<1
0
13
0
0
Hematopoietic growth factors were administered more frequently in the Gemzar-containing arm: granulocyte growth factors (23.6% and 10.1%) and erythropoietic agents (7.3% and 3.9%).
The following clinically relevant, Grade 3 and 4 adverse reactions occurred more frequently in the Gemzar plus carboplatin arm: dyspnea (3.4% versus 2.9%), febrile neutropenia (1.1% versus 0), hemorrhagic event (2.3% versus 1.1 %), motor neuropathy (1.1% versus 0.6%), and rash/desquamation (0.6% versus 0).

Risk SummaryGemzar can cause fetal harm when administered to a pregnant woman. Based on its mechanism of action, Gemzar is expected to result in adverse reproductive effects. Gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits. If Gemzar is used during pregnancy, or if the patient becomes pregnant while taking Gemzar, the patient should be apprised of the potential hazard to a fetus.

Animal DataGemcitabine is embryotoxic causing fetal malformations (cleft palate, incomplete ossification) at doses of 1.5 mg/kg/day in mice (approximately 0.005 times the recommended human dose on a mg/m2 basis). Gemcitabine is fetotoxic causing fetal malformations (fused pulmonary artery, absence of gall bladder) at doses of 0.1 mg/kg/day in rabbits (about 0.002 times the recommended human dose on a mg/m2 basis). Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and developmental delays. [See Warnings and Precautions (5.6)].

Absorption and DistributionThe pharmacokinetics of gemcitabine were examined in 353 patients, with various solid tumors. Pharmacokinetic parameters were derived using data from patients treated for varying durations of therapy given weekly with periodic rest weeks and using both short infusions (<70 minutes) and long infusions (70 to 285 minutes). The total Gemzar dose varied from 500 to 3600 mg/m2.
The volume of distribution was increased with infusion length. Volume of distribution of gemcitabine was 50 L/m2 following infusions lasting <70 minutes. For long infusions, the volume of distribution rose to 370 L/m2.
Gemcitabine pharmacokinetics are linear and are described by a 2-compartment model. Population pharmacokinetic analyses of combined single and multiple dose studies showed that the volume of distribution of gemcitabine was significantly influenced by duration of infusion and gender. Gemcitabine plasma protein binding is negligible.

MetabolismGemcitabine disposition was studied in 5 patients who received a single 1000 mg/m2/30 minute infusion of radiolabeled drug. Within one (1) week, 92% to 98% of the dose was recovered, almost entirely in the urine. Gemcitabine (<10%) and the inactive uracil metabolite, 2′-deoxy-2′,2′-difluorouridine (dFdU), accounted for 99% of the excreted dose. The metabolite dFdU is also found in plasma.
The active metabolite, gemcitabine triphosphate, can be extracted from peripheral blood mononuclear cells. The half-life of the terminal phase for gemcitabine triphosphate from mononuclear cells ranges from 1.7 to 19.4 hours.

EliminationClearance of gemcitabine was affected by age and gender. The lower clearance in women and the elderly results in higher concentrations of gemcitabine for any given dose. Differences in either clearance or volume of distribution based on patient characteristics or the duration of infusion result in changes in half-life and plasma concentrations. Table 10 shows plasma clearance and half-life of gemcitabine following short infusions for typical patients by age and gender.
Table 10: Gemcitabine Clearance and Half-Life for the “Typical” Patient
a Half-life for patients receiving <70 minute infusion.
Age
Clearance Men(L/hr/m2)
Clearance Women(L/hr/m2)
Half-Lifea Men(min)
Half-Lifea Women(min)
29
92.2
69.4
42
49
45
75.7
57.0
48
57
65
55.1
41.5
61
73
79
40.7
30.7
79
94
Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions.

Drug InteractionsWhen Gemzar (1250 mg/m2 on Days 1 and 8) and cisplatin (75 mg/m2 on Day 1) were administered in NSCLC patients, the clearance of gemcitabine on Day 1 was 128 L/hr/m2 and on Day 8 was 107 L/hr/m2. Analysis of data from metastatic breast cancer patients shows that, on average, Gemzar has little or no effect on the pharmacokinetics (clearance and half-life) of paclitaxel and paclitaxel has little or no effect on the pharmacokinetics of gemcitabine. Data from NSCLC patients demonstrate that Gemzar and carboplatin given in combination does not alter the pharmacokinetics of gemcitabine or carboplatin compared to administration of either single agent. However, due to wide confidence intervals and small sample size, interpatient variability may be observed.

28-Day ScheduleA multinational, randomized trial compared Gemzar plus cisplatin to cisplatin alone in the treatment of patients with inoperable Stage IIIA, IIIB, or IV NSCLC who had not received prior chemotherapy. Patients were randomized to receive Gemzar 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle with cisplatin 100 mg/m2 administered on Day 1 of each cycle or to receive cisplatin 100 mg/m2 on Day 1 of each 28-day cycle. The primary efficacy outcome measure was overall survival. A total of 522 patients were enrolled at clinical centers in Europe, the US, and Canada. Patient demographics and baseline characteristics (shown in Table 14) were similar between arms with the exception of histologic subtype of NSCLC, with 48% of patients on the cisplatin arm and 37% of patients on the Gemzar plus cisplatin arm having adenocarcinoma. Efficacy results are presented in Table 14 and Figure 3 for overall survival.

21-Day ScheduleA randomized (1:1), multicenter trial was conducted in 135 patients with Stage IIIB or IV NSCLC. Patients were randomized to receive Gemzar 1250 mg/m2 on Days 1 and 8, and cisplatin 100 mg/m2 on Day 1 of a 21-day cycle or to receive etoposide 100 mg/m2 intravenously on Days 1, 2, and 3 and cisplatin 100 mg/m2 on Day 1 of a 21 -day cycle.
There was no significant difference in survival between the two treatment arms (Log rank p=0.18, two-sided, see Table 14). The median survival was 8.7 months for the Gemzar plus cisplatin arm versus 7.0 months for the etoposide plus cisplatin arm. Median time to disease progression for the Gemzar plus cisplatin arm was 5.0 months compared to 4.1 months on the etoposide plus cisplatin arm (Log rank p=0.015, two-sided). The objective response rate for the Gemzar plus cisplatin arm was 33% compared to 14% on the etoposide plus cisplatin arm (Fisher's Exact p=0.01, two-sided).
Figure 3: Kaplan-Meier Survival Curve in Gemzar plus Cisplatin versus Cisplatin in Patients with NSCLC Study (N=522).
Table 14: Randomized Trials of Gemzar plus Cisplatin in Patients with NSCLC
a 28-day schedule — Gemzar plus cisplatin: Gemzar 1000 mg/m2 on Days 1, 8, and 15 and cisplatin 100 mg/m2 on Day 1 every 28 days; Single-agent cisplatin: cisplatin 100 mg/m2 on Day 1 every 28 days.
b 21-day schedule — Gemzar plus cisplatin: Gemzar 1250 mg/m2 on Days 1 and 8 and cisplatin 100 mg/m2 on Day 1 every 21 days; Etoposide plus Cisplatin: cisplatin 100 mg/m2 on Day 1 and intravenous etoposide 100 mg/m2 on Days 1, 2, and 3 every 21 days.
c N/A Not applicable.
d Karnofsky Performance Status.
e CI=confidence intervals.
f p-value two-sided Fisher's Exact test for difference in binomial proportions; log rank test for time-to-event analyses.
Trial
28-day Schedulea21-day SchedulebTreatment Arm
Gemzar plus Cisplatin
Cisplatin
Gemzar plus Cisplatin
Etoposide plus Cisplatin
Number of patients
260
262
69
66
Demographic/Entry Characteristics     Male
70%
71%
93%
92%
Median age, years
62
63
58
60
     Range
36 to 88
35 to 79
33 to 76
35 to 75
Stage IIIA
7%
7%
N/AcN/AcStage IIIB
26%
23%
48%
52%
Stage IV
67%
70%
52%
49%
Baseline KPSd 70 to 80
41%
44%
45%
52%
Baseline KPSd 90 to 100
57%
55%
55%
49%
Efficacy OutcomesSurvival
     Median in months
9.0
7.6
8.7
7.0
     (95% CIe) months
8.2, 11.0
6.6, 8.8
7.8, 10.1
6.0, 9.7
p-valuefp=0.008
p=0.18
Time to Disease Progression
     Median in months
5.2
3.7
5.0
4.1
     (95% CIe) months
4.2, 5.7
3.0, 4.3
4.2, 6.4
2.4, 4.5
     p-valuefp=0.009
p=0.015
Tumor Response
26%
10%
33%
14%
     p-valuefp<0.0001
p=0.01

2.5 Dose Modifications For Non-Hematologic Adverse Reactions

  • Permanently discontinue Gemzar for any of the following:
  • Unexplained dyspnea or other evidence of severe pulmonary toxicity
  • Severe hepatic toxicity
  • Hemolytic-uremic syndrome
  • Capillary leak syndrome
  • Posterior reversible encephalopathy syndrome
  • Withhold Gemzar or reduce dose by 50% for other severe (Grade 3 or 4) non-hematological toxicity until resolved. No dose modifications are recommended for alopecia, nausea, or vomiting.

2.6 Preparation And Administration Precautions

Exercise caution and wear gloves when preparing Gemzar solutions. Immediately wash the skin thoroughly or rinse the mucosa with copious amounts of water if Gemzar contacts the skin or mucus membranes. Death has occurred in animal studies due to dermal absorption. For further guidance on handling Gemzar go to “OSHA Hazardous Drugs” (refer to antineoplastic weblinks including OSHA Technical Manual) at OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html

2.7 Preparation For Intravenous Infusion Administration

Reconstitute the vials with 0.9% Sodium Chloride Injection without preservatives.
Add 5 mL to the 200-mg vial or 25 mL to the 1-g vial. These dilutions each yield a Gemzar concentration of 38 mg/mL. Complete withdrawal of the vial contents will provide 200 mg or 1 g of Gemzar. Prior to administration the appropriate amount of drug must be diluted with 0.9% Sodium Chloride Injection. Final concentrations may be as low as 0.1 mg/mL.
Reconstituted Gemzar is a clear, colorless to light straw-colored solution. Inspect visually prior to administration and discard for particulate matter or discoloration. Gemzar solutions are stable for 24 hours at controlled room temperature of 20° to 25°C (68° to 77°F). Do not refrigerate as crystallization can occur.
No incompatibilities have been observed with infusion bottles or polyvinyl chloride bags and administration sets.

3 Dosage Forms And Strengths

Gemzar (gemcitabine for injection USP) is a white to off-white lyophilized powder available in sterile single-use vials containing 200 mg or 1 g gemcitabine.

4 Contraindications

Gemzar is contraindicated in patients with a known hypersensitivity to gemcitabine.

5.1 Schedule-Dependent Toxicity

In clinical trials evaluating the maximum tolerated dose of Gemzar, prolongation of the infusion time beyond 60 minutes or more frequent than weekly dosing resulted in an increased incidence of clinically significant hypotension, severe flu-like symptoms, myelosuppression, and asthenia. The half-life of Gemzar is influenced by the length of the infusion [see Clinical Pharmacology (12.3)].

5.2 Myelosuppression

Myelosuppression manifested by neutropenia, thrombocytopenia, and anemia occurs with Gemzar as a single agent and the risks are increased when Gemzar is combined with other cytotoxic drugs. In clinical trials, Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 25%, 8%, and 5%, respectively of patients receiving single-agent Gemzar. The frequencies of Grade 3-4 neutropenia, anemia, and thrombocytopenia varied from 48% to 71%, 8 to 28%, and 5 to 55%, respectively, in patients receiving Gemzar in combination with another drug.

5.3 Pulmonary Toxicity And Respiratory Failure

Pulmonary toxicity, including interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome (ARDS), has been reported. In some cases, these pulmonary events can lead to fatal respiratory failure despite discontinuation of therapy. The onset of pulmonary symptoms may occur up to 2 weeks after the last dose of Gemzar. Discontinue Gemzar in patients who develop unexplained dyspnea, with or without bronchospasm, or have any evidence of pulmonary toxicity [see Adverse Reactions (6.1 and 6.2)].

5.4 Hemolytic Uremic Syndrome

Hemolytic uremic syndrome, including fatalities from renal failure or the requirement for dialysis, can occur in patients treated with Gemzar. In clinical trials, HUS was reported in 6 of 2429 patients (0.25%). Most fatal cases of renal failure were due to HUS [see Adverse Reactions (6.1 and 6.2)]. Assess renal function prior to initiation of Gemzar and periodically during treatment. Consider the diagnosis of HUS in patients who develops anemia with evidence of microangiopathic hemolysis, elevation of bilirubin or LDH, or reticulocytosis; severe thrombocytopenia; or evidence of renal failure (elevation of serum creatinine or BUN) [see Dosage and Administration (2.5) and Use in Specific Populations (8.6)]. Permanently discontinue Gemzar in patients with HUS or severe renal impairment. Renal failure may not be reversible even with discontinuation of therapy.

5.5 Hepatic Toxicity

Drug-induced liver injury, including liver failure and death, has been reported in patients receiving Gemzar alone or in combination with other potentially hepatotoxic drugs [see Adverse Reactions (6.1 and 6.2)]. Administration of Gemzar in patients with concurrent liver metastases or a pre-existing medical history or hepatitis, alcoholism, or liver cirrhosis can lead to exacerbation of the underlying hepatic insufficiency [see Use in Specific Populations (8.7)]. Assess hepatic function prior to initiation of Gemzar and periodically during treatment. Discontinue Gemzar in patients that develop severe liver injury.

5.6 Embryofetal Toxicity

Gemzar can cause fetal harm when administered to a pregnant woman, based on its mechanism of action. Gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits. If this drug is used during pregnancy, or if a woman becomes pregnant while taking Gemzar, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1)].

5.7 Exacerbation Of Radiation Therapy Toxicity

Gemzar is not indicated for use in combination with radiation therapy.

5.8 Capillary Leak Syndrome

Capillary leak syndrome (CLS) with severe consequences has been reported in patients receiving Gemzar as a single agent or in combination with other chemotherapeutic agents. Discontinue Gemzar if CLS develops during therapy.

5.9 Posterior Reversible Encephalopathy Syndrome

Posterior reversible encephalopathy syndrome (PRES) has been reported in patients receiving Gemzar as a single agent or in combination with other chemotherapeutic agents. PRES can present with headache, seizure, lethargy, hypertension, confusion, blindness, and other visual and neurologic disturbances. Confirm the diagnosis of PRES with magnetic resonance imaging (MRI) and discontinue Gemzar if PRES develops during therapy.

6 Adverse Reactions

  • The following serious adverse reactions are discussed in greater detail in another section of the label
  • Schedule-dependent Toxicity [see Warnings and Precautions (5.1)]Myelosuppression [see Warnings and Precautions (5.2)]Pulmonary Toxicity and Respiratory Failure [see Warnings and Precautions (5.3)]Hemolytic Uremic Syndrome [see Warnings and Precautions (5.4)]Hepatic Toxicity [see Warnings and Precautions (5.5)]Embryofetal Toxicity [see Warnings and Precautions (5.6), Use in Specific Populations (8.1), and Nonclinical Toxicology (13.1)]Exacerbation of Radiation Toxicity [see Warnings and Precautions (5.7)]Capillary Leak Syndrome [see Warnings and Precautions (5.8)]Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.9)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

6.2 Post-Marketing Experience

The following adverse reactions have been identified during post-approval use of Gemzar. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiovascular — Congestive heart failure, myocardial infarction, arrhythmias, supraventricular arrhythmias
Vascular Disorders — Peripheral vasculitis, gangrene, and capillary leak syndrome [see Warnings and Precautions (5.8)]Skin — Cellulitis, severe skin reactions, including desquamation and bullous skin eruptions
Hepatic — Hepatic failure, hepatic veno-occlusive disease
Pulmonary — Interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome (ARDS)
Nervous System — Posterior reversible encephalopathy syndrome (PRES) [see Warnings and Precautions (5.9)]

7 Drug Interactions

No drug interaction studies have been conducted.

8.1 Pregnancy

Pregnancy Category D. [See Warnings and Precautions (5.6)].

8.3 Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Gemzar, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

The safety and effectiveness of Gemzar have not been established in pediatric patients. The safety and pharmacokinetics of gemcitabine were evaluated in a trial in pediatric patients with refractory leukemia. The maximum tolerated dose was 10 mg/m2/min for 360 minutes weekly for three weeks followed by a one-week rest period. The safety and activity of Gemzar were evaluated in a trial of pediatric patients with relapsed acute lymphoblastic leukemia (22 patients) and acute myelogenous leukemia (10 patients) at a dose of 10 mg/m2/min administered over 360 minutes weekly for three weeks followed by a one-week rest period. Patients with M1 or M2 bone marrow on Day 28 who did not experience unacceptable toxicity were eligible to receive a maximum of one additional four-week course. Toxicities observed included bone marrow suppression, febrile neutropenia, elevation of serum transaminases, nausea, and rash/desquamation. No meaningful clinical activity was observed in this trial.

8.5 Geriatric Use

In clinical studies of GEMZAR, enrolling 979 patients with various cancers who received GEMZAR as a single agent, no overall differences in safety were observed between patients aged 65 and older and younger patients, with the exception of a higher rate of Grade 3-4 thrombocytopenia in older patients as compared to younger patients. In a randomized trial in women with ovarian cancer, 175 women received GEMZAR plus carboplatin, of which 29% were age 65 years or older. Similar effectiveness was observed between older and younger women. There was significantly higher Grade 3/4 neutropenia in women 65 years of age or older.
GEMZAR clearance is affected by age, however there are no recommended dose adjustments based on patients' age [see Clinical Pharmacology (12.3)].

8.6 Renal Impairment

No clinical studies have been conducted with gemcitabine in patients with decreased renal function.

8.7 Hepatic Impairment

No clinical studies have been conducted with gemcitabine in patients with decreased hepatic function.

8.8 Gender

Gemzar clearance is affected by gender [see Clinical Pharmacology (12.3)]. In single-agent studies of Gemzar, women, especially older women, were more likely not to proceed to a subsequent cycle and to experience Grade 3/4 neutropenia and thrombocytopenia.

10 Overdosage

Myelosuppression, paresthesias, and severe rash were the principal toxicities seen when a single dose as high as 5700 mg/m2 was administered by intravenous infusion over 30 minutes every 2 weeks to several patients in a dose-escalation study.

11 Description

Gemzar (gemcitabine for injection, USP) is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HCl is 2′-deoxy-2′,2′-difluorocytidine monohydrochloride (β-isomer).
The structural formula is as follows:
The empirical formula for gemcitabine HCl is C9H11F2N3O4 • HCl. It has a molecular weight of 299.66.
Gemcitabine HCl is soluble in water, slightly soluble in methanol, and practically insoluble in ethanol and polar organic solvents.
Gemzar is supplied in a sterile form for intravenous use only. Vials of Gemzar contain either 200 mg or 1 g of gemcitabine HCl (expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.

12.1 Mechanism Of Action

Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside triphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabine triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP by the action of the diphosphate enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabine nucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands, which eventually results in the initiation of apoptotic cell death.

13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility

Long-term animal studies to evaluate the carcinogenic potential of Gemzar have not been conducted. Gemcitabine was mutagenic in an in vitro mouse lymphoma (L5178Y) assay and was clastogenic in an in vivo mouse micronucleus assay. Gemcitabine IP doses of 0.5 mg/kg/day (about 1/700 the human dose on a mg/m2 basis) in male mice had an effect on fertility with moderate to severe hypospermatogenesis, decreased fertility, and decreased implantations. In female mice, fertility was not affected but maternal toxicities were observed at 1.5 mg/kg/day administered intravenously (about 1/200 the human dose on a mg/m2 basis) and fetotoxicity or embryolethality was observed at 0.25 mg/kg/day administered intravenously (about 1/1300 the human dose on a mg/m2 basis).

14.1 Ovarian Cancer

The safety and efficacy of Gemzar was studied in a randomized trial of 356 women with advanced ovarian cancer that had relapsed at least 6 months after first-line platinum-based therapy. Patients were randomized to receive either Gemzar 1000 mg/m2 on Days 1 and 8 of a 21-day cycle and carboplatin AUC 4 administered after Gemzar infusion on Day 1 of each cycle (n=178) or to carboplatin AUC 5 administered on Day 1 of each 21-day cycle (n=178). The primary efficacy outcome measure was progression free survival (PFS).
Patient characteristics are shown in Table 11. The addition of Gemzar to carboplatin resulted in statistically significant improvements in PFS and overall response rate as shown in Table 12 and Figure 1. Approximately 75% of patients in each arm received additional chemotherapy for disease progression; 13 of 120 patients in the carboplatin alone arm received Gemzar for treatment of disease progression. There was no significant difference in overall survival between the treatment arms.
Table 11: Randomized Trial of Gemzar plus Carboplatin versus Carboplatin in Ovarian Cancer - Baseline Demographics and Clinical Characteristics
a 5 patients on Gemzar plus carboplatin arm and 4 patients on carboplatin arm with no baseline Eastern Cooperative Oncology Group (ECOG) performance status.
b 2 on Gemzar plus carboplatin arm and 1 on carboplatin arm had platinum-free interval <6 months.
Gemzar/Carboplatin
Carboplatin
 Number of randomized patients
178
178
 Median age, years
59
58
     Range
36 to 78
21 to 81
 Baseline ECOG performance status 0-1a94%
95%
 Disease Status
     Evaluable
8%
3%
     Bidimensionally measurable
92%
96%
 Platinum-free intervalb     6-12 months
40%
40%
     >12 months
59%
60%
 First-line therapy
     Platinum-taxane combination
70%
71%
     Platinum-non-taxane combination
29%
28%
     Platinum monotherapy
1%
1%
Table 12: Randomized Trial of Gemzar plus Carboplatin versus Carboplatin in Ovarian Cancer - Efficacy Outcomes
a CI=confidence interval.
b Log rank, unadjusted.
c Chi square.
d CR=Complete response.
e PR plus PRNM=Partial response plus partial response, non-measurable disease.
f Independently reviewed cohort - Gemzar/carboplatin (n=121), carboplatin (n=101); independent reviewers unable to measure disease detected by sonography or physical exam.
Gemzar/Carboplatin(N=178)
Carboplatin(N=178)
Progression-free Survival
     Median (95% CIa) months
8.6 (8.0, 9.7)
5.8 (5.2, 7.1)
     Hazard Ratio (95% CI)
0.72 (0.57, 0.90)
     p-valuebp=0.0038
Overall Survival
     Median (95% CI) months
18.0 (16.2, 20.3)
17.3 (15.2, 19.3)
     Hazard Ratio (95% CI)
0.98 (0.78, 1.24)
     p-valuebp=0.8977
Investigator Reviewed
Overall Response Rate
47.2%
30.9%
     p-valuecp=0.0016
     CRd14.6%
6.2%
     PR plus PRNMe32.6%
24.7%
Independently Reviewed
Overall Response Ratef46.3%
35.6%
     p-valuecp=0.11
     CRd9.1%
4.0%
     PR plus PRNMe37.2%
31.7%
Figure 1: Kaplan-Meier Curve of Progression Free Survival in Gemzar plus Carboplatin versus Carboplatin in Ovarian Cancer (N=356).

14.2 Breast Cancer

The safety and efficacy of Gemzar were evaluated in a multi-national, randomized, open-label trial conducted in women receiving initial treatment for metastatic breast cancer in women who have received prior adjuvant/neoadjuvant anthracycline chemotherapy unless clinically contraindicated. Patients were randomized to receive Gemzar 1250 mg/m2 on Days 1 and 8 of a 21-day cycle and paclitaxel 175 mg/m2 administered prior to Gemzar on Day 1 of each cycle (n=267) or to receive paclitaxel 175 mg/m2 was administered on Day 1 of each 21-day cycle (n=262). The primary efficacy outcome measure was time to documented disease progression.
A total of 529 patients were enrolled; 267 were randomized to Gemzar and paclitaxel and 262 to paclitaxel alone. Demographic and baseline characteristics were similar between treatment arms (see Table 13). Efficacy results are presented in Table 13 and Figure 2. The addition of Gemzar to paclitaxel resulted in statistically significant improvement in time to documented disease progression and overall response rate compared to paclitaxel alone. There was no significant difference in overall survival.
Table 13: Randomized Trial of Gemzar plus Paclitaxel versus Paclitaxel in Breast Cancer
a Karnofsky Performance Status.
b These represent reconciliation of investigator and Independent Review Committee assessments according to a predefined algorithm.
c Based on the ITT population.
Gemzar/Paclitaxel
Paclitaxel
Number of patients
267
262
Demographic/Entry Characteristics   Median age (years)
53
52
         Range
26 to 83
26 to 75
   Metastatic disease
97%
97%
   Baseline KPSa ≥90
70%
74%
   Number of tumor sites
         1-2
57%
59%
         ≥3
43%
41%
   Visceral disease
73%
73%
   Prior anthracycline
97%
96%
Efficacy Outcomes   Time to Documented Disease Progressionb         Median in months(95% CI)
5.2(4.2, 5.6)
2.9(2.6, 3.7)
         Hazard Ratio (95% CI)
0.650 (0.524, 0.805)
   p-value
p<0.0001
   Overall Survivalc         Median Survival in months(95% CI)
18.6(16.5, 20.7)
15.8(14.1, 17.3)
         Hazard Ratio (95% CI)
0.86 (0.71, 1.04)
   p-value
Not Significant
   Overall Response Rate
40.8%
22.1%
         (95% CI)
(34.9, 46.7)
(17.1, 27.2)
   p-value
p<0.0001
Figure 2: Kaplan-Meier Curve of Time to Documented Disease Progression in Gemzar plus Paclitaxel versus Paclitaxel Breast Cancer Study (N=529).

14.3 Non-Small Cell Lung Cancer (Nsclc)

The safety and efficacy of Gemzar was evaluated in two randomized, multicenter trials.

14.4 Pancreatic Cancer

  • The safety and efficacy of Gemzar was evaluated in two trials, a randomized, single-blind, two-arm, active-controlled trial conducted in patients with locally advanced or metastatic pancreatic cancer who had received no prior chemotherapy and in a single-arm, open-label, multicenter trial conducted in patients with locally advanced or metastatic pancreatic cancer previously treated with 5-FU or a 5-FU-containing regimen. The first trial randomized patients to receive Gemzar 1000 mg/m2 intravenously over 30 minutes once weekly for 7 weeks followed by a one-week rest, then once weekly dosing for 3 consecutive weeks every 28-days in subsequent cycles (n=63) or to 5-fluorouracil (5-FU) 600 mg/m2 intravenously over 30 minutes once weekly (n=63). In the second trial, all patients received Gemzar 1000 mg/m2 intravenously over 30 minutes once weekly for 7 weeks followed by a one-week rest, then once weekly dosing for 3 consecutive weeks every 28-days in subsequent cycles.
  • The primary efficacy outcome measure in both trials was "clinical benefit response". A patient was considered to have had a clinical benefit response if either of the following occurred:
  • The patient achieved a ≥50% reduction in pain intensity (Memorial Pain Assessment Card) or analgesic consumption, or a 20-point or greater improvement in performance status (Karnofsky Performance Status) for a period of at least 4 consecutive weeks, without showing any sustained worsening in any of the other parameters. Sustained worsening was defined as 4 consecutive weeks with either any increase in pain intensity or analgesic consumption or a 20-point decrease in performance status occurring during the first 12 weeks of therapy.
  • OR
  • The patient was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation.
  • The randomized trial enrolled 126 patients across 17 sites in the US and Canada. The demographic and entry characteristics were similar between the arms (Table 15). The efficacy outcome results are shown in Table 15 and for overall survival in Figure 4. Patients treated with Gemzar had statistically significant increases in clinical benefit response, survival, and time to disease progression compared to those randomized to receive 5-FU. No confirmed objective tumor responses were observed in either treatment arm.
  • Table 15: Randomized Trial of Gemzar versus 5-Fluorouracil in Pancreatic Cancer
  • A Karnofsky Performance Status.
  • B p-value for clinical benefit response calculated using the two-sided test for difference in binomial proportions. All other p-values are calculated using log rank test.
  • Gemzar
  • 5-FU
  • Number of patients
  • 63
  • 63
  • Demographic/Entry Characteristics      Male
  • 54%
  • 54%
  • Median age
  • 62 years
  • 61 years
  • Range
  • 37 to 79
  • 36 to 77
  • Stage IV disease
  • 71%
  • 76%
  • Baseline KPSa ≤70
  • 70%
  • 68%
  • Efficacy OutcomesClinical benefit response
  • 22.2%
  • 4.8%
  • P-valuebp=0.004
  • Survival
  • Median
  • 5.7 months
  • 4.2 months
  • (95% CI)
  • (4.7, 6.9)
  • (3.1, 5.1)
  • P-valuebp=0.0009
  • Time to Disease Progression
  • Median
  • 2.1 months
  • 0.9 months
  • (95% CI)
  • (1.9, 3.4)
  • (0.9, 1.1)
  • P-valuebp=0.0013
  • Figure 4: Kaplan-Meier Survival Curve.

16.1 How Supplied

Gemzar (gemcitabine for injection, USP), is available in sterile single-use vials individually packaged in a carton containing:
200 mg white to off-white, lyophilized powder in a 10-mL size sterile single-use vial – NDC 0002-7501-01 (No. 7501)
1 g white to off-white, lyophilized powder in a 50-mL size sterile single-use vial – NDC 0002-7502-01 (No. 7502)

16.2 Storage And Handling

Unopened vials of Gemzar are stable until the expiration date indicated on the package when stored at controlled room temperature 20° to 25°C (68° to 77°F) and that allows for excursions between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature] [see Dosage and Administration (2.6 and 2.7)].

17 Patient Counseling Information

  • Advise patients of the risks of low blood cell counts and the potential need for blood transfusions and increased susceptibility to infections. Instruct patients to immediately contact their healthcare provided for development of signs or symptoms of infection, fever, prolonged or unexpected bleeding, bruising, or shortness of breath [see Warnings and Precautions (5.2)].
  • Advise patients of the risks of pulmonary toxicity including respiratory failure and death. Instruct patients to immediately contact their healthcare provider for development of shortness of breath, wheezing, or cough [see Warnings and Precautions (5.3)].
  • Advise patients of the risks of hemolytic-uremic syndrome and associated renal failure. Instruct patients to immediately contact their healthcare provider for changes in the color or volume of urine output or for increased bruising or bleeding [see Warnings and Precautions (5.4)].
  • Advise patients of the risks of hepatic toxicity including liver failure and death. Instruct patients to immediately contact their healthcare provider for signs of jaundice or for pain/tenderness in the right upper abdominal quadrant [see Warnings and Precautions (5.5)].
  • Marketed by: Lilly USA, LLC Indianapolis, IN 46285, USACopyright © 1996, 2017, Eli Lilly and Company. All rights reserved.GEM-0003-USPI-20170913

* Please review the disclaimer below.

Previous Code
0002-7335
Next Code
0002-7502